Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Expenses (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Operating Expenses for 4 consecutive years, with $68.5 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 8.19% to $68.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $222.7 million through Dec 2025, up 10.76% year-over-year, with the annual reading at $222.7 million for FY2025, 10.76% up from the prior year.
  • Operating Expenses for Q4 2025 was $68.5 million at Centessa Pharmaceuticals, up from $53.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $74.6 million in Q4 2024, with the low at $36.1 million in Q1 2024.
  • Average Operating Expenses over 4 years is $50.8 million, with a median of $47.9 million recorded in 2023.
  • The sharpest move saw Operating Expenses plummeted 31.27% in 2023, then skyrocketed 77.44% in 2024.
  • Over 4 years, Operating Expenses stood at $41.6 million in 2022, then increased by 1.03% to $42.0 million in 2023, then surged by 77.44% to $74.6 million in 2024, then fell by 8.19% to $68.5 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $68.5 million, $53.8 million, and $54.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.